We show that the EGCG–p53 interaction disrupts p53 interaction with MDM2 and inhibits ubiquitination of p53, likely stabilizing p53 for anti-tumor activity, providing a structural mechanism for the anti-cancer effect of EGCG. This evidence concerns the gene MDM2 and cancer.